List of drugs for medical insurance negotiation access may be announced on November 28

The list of drugs for negotiation and access of national health insurance is scheduled to be released tomorrow (November 28), which also means that the 2019 version of national health insurance catalog is finally completed At that time, the state health insurance bureau will hold a press conference to introduce the list Please pay attention! In August this year, the national medical insurance drug catalog was released to the public in 2019 After that, according to the expert review and selection vote, 128 drugs were initially determined to be included in the scope of access to the proposed negotiation, including 109 western drugs and 19 Chinese patent drugs These drugs are mainly used in the treatment of cancer, rare diseases and other major diseases, hepatitis C, hepatitis B, hypertension, diabetes and other chronic diseases Many of these products are new drugs approved by the State Food and drug administration, including major innovative drugs in China In the middle of November, the state health insurance bureau organized a new round of negotiations on medical insurance access In addition to the highly popular anticancer drugs (PD-1) in the market itself, the hypoglycemic products in the field of chronic diseases also appear in the medical insurance negotiation catalogue, which is conducive to reducing the burden of long-term medication for some patients with chronic diseases Mengmeng statement: this view only represents the author and does not represent the position of yaozhi.com You are welcome to exchange and supplement in the message area If you need to reprint, please be sure to indicate the author and source of the article.